HHS proposed moving cannabis from its current status as a Schedule I substance to a Schedule III substance under the Controlled Substances Act (CSA). The DEA maintains that it should have the final authority on scheduling cannabis under the CSA and is questioning the basis for HHS’s suggested changes. In recent years, the federal government’s stance on cannabis has been under intense scrutiny. However, such a move would undoubtedly have significant implications for the industry around state-legal cannabis companies. This heightened attention reached new heights when the U.S. Department of Health and Human Services (HHS) recommended a significant change in the drug’s classification last August.
In recent years, the federal government’s stance on cannabis has been under intense scrutiny. This heightened attention reached new heights when the U.S. Department of Health and Human Services (HHS) recommended a significant change in the drug’s classification last August.
HHS proposed moving cannabis from its current status as a Schedule I substance to a Schedule III substance under the Controlled Substances Act (CSA). This recommendation was based on a comprehensive analysis of cannabis research and legalization experiments conducted nationwide.
DEA Skepticism on the Accuracy of HHS Recommendations
According...
Read the full article @ Marijuana Index